Net Loss Per Share

6 Months Ended

Jun. 30, 2021

Net Loss Per Share

Net Loss Per Share

13.          Net Loss Per Share

The following table sets forth the basic and diluted net loss per share computation and provides a reconciliation of the numerator and denominator for the periods presented:

	Three Months Ended June 30,				Six Months Ended June 30,
(In thousands, except per share data)	2021		2020		2021		2020
Numerator:
Net loss attributable to CASI Pharmaceuticals, Inc.	$	(6,946)	$	(8,694)	$	(20,829)	$	(17,135)
Denominator:
Weighted average number of common shares		139,797		100,921		132,352		99,847
Denominator for basic and diluted net loss per share calculation		139,797		100,921		132,352		99,847
Net loss per share
— Basic and diluted	$	(0.05)	$	(0.09)	$	(0.16)	$	(0.17)

As of June 30, 2021, and 2020, outstanding stock options totaling 24,780,540 and 15,906,321, respectively, and outstanding warrants totaling 8,271,709 and 8,271,709, respectively, were anti-dilutive, and therefore, were not included in the computation of weighted average shares used in computing diluted loss per share.